Pulmonale Hypertonie assoziiert mit Lungenerkrankungen

 

 Permissions and Reprints

Zusammenfassung

Nicht selten sind Lungenerkrankungen und Hypoventilationssyndrome mit einer pulmonalen Hypertonie (PH) assoziiert. In den meisten Fällen liegt eine nicht schwere PH vor. Diese ist hämodynamisch definiert durch einen pulmonalarteriellen Mitteldruck (PAPm) > 20 mmHg, einen pulmonalarteriellen Verschlussdruck (PAWP) ≤ 15 mmHg und einen pulmonal-vaskulären Widerstand von ≤ 5 Wood-Einheiten (WU). Sowohl die nicht schwere (PVR ≤ 5 WU) als auch deutlich ausgeprägter die schwere PH (PVR > 5 WU) sind prognostisch ungünstig. Bei Verdacht auf eine PH wird empfohlen, primär zu prüfen, ob Risikofaktoren für eine pulmonalarterielle Hypertonie (PAH, Gruppe 1 PH) oder eine chronisch thromboembolische pulmonale Hypertonie (CTEPH, Gruppe 4 PH) vorliegen. Falls Risikofaktoren vorliegen oder bei Lungenkranken der Verdacht auf eine schwere PH besteht, wird eine zeitnahe Vorstellung der Patient*innen in einer PH-Ambulanz empfohlen. Bei Patient*innen mit einer schweren PH assoziiert mit Lungenerkrankungen wird eine personalisierte, individuelle Therapie – möglichst im Rahmen von Therapiestudien – empfohlen. Aktuell sollte bei COPD-Patient*innen nur ein Therapieversuch erwogen werden, wenn die assoziierte PH schwergradig und ein „pulmonalvaskulärer“ Phänotyp (schwere präkapilläre PH, aber typischerweise nur milde bis moderate Atemwegsobstruktion, keine oder milde Hyperkapnie und DLCO < 45 % vom Soll) vorliegt. Bei schwerer PH assoziiert mit einer interstitiellen Lungenerkrankung können entsprechend individueller Abwägung Phosphodiesterase-5-Inhibitoren erwogen werden. Inhaliertes Treprostinil kommt bei diesen Patient*innen auch bei nicht schwerer PH in Betracht.

Abstract

Lung diseases and hypoventilation syndromes are often associated with pulmonary hypertension (PH). In most cases, PH is not severe. This is defined hemodynamically by a mean pulmonary arterial pressure (PAPm) > 20 mmHg, a pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance of ≤ 5 Wood units (WU). Both the non-severe (PVR ≤ 5 WU) and much more the severe PH (PVR > 5 WU) have an unfavorable prognosis.

If PH is suspected, it is recommended to primarily check whether risk factors for pulmonary arterial hypertension (PAH, group 1 PH) or chronic thromboembolic pulmonary hypertension (CTEPH, group 4 PH) are present. If risk factors are present or there is a suspicion of severe PH in lung patients, it is recommended that the patient should be presented to a PH outpatient clinic promptly.

For patients with severe PH associated with lung diseases, personalized, individual therapy is recommended – if possible within the framework of therapy studies. Currently, a therapy attempt with PH specific drugs should only be considered in COPD patients if the associated PH is severe and a “pulmonary vascular” phenotype (severe precapillary PH, but typically only mild to moderate airway obstruction, no or mild hypercapnia and DLCO < 45 % of predicted value) is present. In patients with severe PH associated with interstitial lung disease phosphodiesterase-5-inhibitors may be considered in individual cases. Inhaled treprostinil may be considered also in non-severe PH in this patient population.

Publication History

Article published online:
14 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Kessler R, Faller M, Weitzenblum E. et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-224
  CrossrefPubMedGoogle Scholar
• 2 Oswald-Mammosser M, Weitzenblum E, Quoix E. et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198
  CrossrefPubMedGoogle Scholar
• 3 Cottin V, Le Pavec J, Prévot G. et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111
  CrossrefPubMedGoogle Scholar
• 4 Nathan SD, Barbera JA, Gaine S. et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53: 1801914
  CrossrefPubMedGoogle Scholar
• 5 Thurnheer R, Ulrich S, Bloch KE. Precapillary Pulmonary Hypertension and Sleep-Disordered Breathing: Is There a Link?. Respiration 2017; 93: 65-77
  CrossrefPubMedGoogle Scholar
• 6 Lichtblau M, Saxer S, Furian M. et al. Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m. Eur Respir J 2020; 56: 1902474 DOI: 10.1183/13993003.02474-2019.
  CrossrefPubMedGoogle Scholar
• 7 Leon-Velarde F, Maggiorini M, Reeves JT. et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005; 6: 147-157
  CrossrefPubMedGoogle Scholar
• 8 Freitas CSG, Baldi BG, Jardim C. et al. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet J Rare Dis 2017; 12: 74-80
  CrossrefPubMedGoogle Scholar
• 9 Galie N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975
  CrossrefPubMedGoogle Scholar
• 10 Zeder K, Avian A, Bachmaier G. et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58: 2100
  CrossrefPubMedGoogle Scholar
• 11 Olsson KM, Hoeper MM, Pausch C. et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; DOI: 10.1183/13993003.01483-2021.
  CrossrefPubMedGoogle Scholar
• 12 Chaouat A, Bugnet AS, Kadaoui N. et al. Severe Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005; 172: 189-194
  CrossrefPubMedGoogle Scholar
• 13 Lettieri CJ, Nathan SD, Barnett SD. et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752
  CrossrefPubMedGoogle Scholar
• 14 Medrek SK, Sharafkhaneh A, Spiegelman AM. et al. Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population. COPD 2017; 14: 484-489
  CrossrefPubMedGoogle Scholar
• 15 Kessler R, Faller M, Fourgaut G. et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158-164
  CrossrefPubMedGoogle Scholar
• 16 Hurdman J, Condliffe R, Elliot CA. et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41: 1292-1301
  CrossrefPubMedGoogle Scholar
• 17 Vizza CD, Hoeper MM, Huscher D. et al. Pulmonary hypertension in patients with chronic obstructive lung disease: results from COMPERA. Chest 2021; DOI: 10.1016/j.chest.2021.02.012.
  CrossrefPubMedGoogle Scholar
• 18 Dauriat G, Reynaud-Gaubert M, Cottin V. et al. Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. J Heart Lung Transplant 2021; 40: 1009-1018
  CrossrefPubMedGoogle Scholar
• 19 Yogeswaran A, Kuhnert S, Gall H. et al. Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study. Front Cardiovasc Med 2022; 9: 826369
  CrossrefPubMedGoogle Scholar
• 20 Kovacs G, Agusti A, Barbera JA. et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is there a Pulmonary Vascular Phenotype?. Am J Respir Crit Care Med 2018; 198: 1000-1011
  CrossrefPubMedGoogle Scholar
• 21 Andersen KH, Iversen M, Kjaergaard J. et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. The Journal of Heart and Lung Transplantation 2012; 31: 373-380
  CrossrefPubMedGoogle Scholar
• 22 Thabut G, Dauriat G, Stern JB. et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-1536
  CrossrefPubMedGoogle Scholar
• 23 Lewis RA, Thompson AAR, Billings CG. et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020; 55: 2000041 DOI: 10.1183/13993003.00041-2020.
  CrossrefPubMedGoogle Scholar
• 24 Bunel V, Guyard A, Dauriat G. et al. Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. Chest 2019; 156: 33-44
  CrossrefPubMedGoogle Scholar
• 25 Carlsen J, Hasseriis Andersen K, Boesgaard S. et al. Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant 2013; 32: 347-354
  CrossrefPubMedGoogle Scholar
• 26 Hoeper MM, Dwivedi K, Pausch C. et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med 2022; 10: 937-948
  CrossrefPubMedGoogle Scholar
• 27 Kovacs G, Avian A, Douschan P. et al. Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?. European Respiratory Journal 2016; 48: PA2395
  PubMedGoogle Scholar
• 28 Torres-Castro R, Gimeno-Santos E, Vilaró J. et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. Eur Respir Rev 2021; 30: 200321 DOI: 10.1183/16000617.0321-2020.
  CrossrefPubMedGoogle Scholar
• 29 Nathan SD, Shlobin OA, Barnett SD. et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1305-1310
  CrossrefPubMedGoogle Scholar
• 30 Fisher MR, Forfia PR, Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621
  CrossrefPubMedGoogle Scholar
• 31 Arcasoy SM, Christie JD, Ferrari VA. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740
  CrossrefPubMedGoogle Scholar
• 32 Bax S, Bredy C, Kempny A. et al. A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Res 2018; 4: 00124-2017
  CrossrefPubMedGoogle Scholar
• 33 Bax S, Jacob J, Ahmed R. et al. Right Ventricular to Left Ventricular Ratio at CT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease. Chest 2020; 157: 89-98
  CrossrefPubMedGoogle Scholar
• 34 Chin M, Johns C, Currie BJ. et al. Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. Front Cardiovasc Med 2018; 5: 53
  CrossrefPubMedGoogle Scholar
• 35 Kiely DG, Levin D, Hassoun P. et al. EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulm Circ 2019; 9: 2045894019841990
  CrossrefPubMedGoogle Scholar
• 36 Swift AJ, Dwivedi K, Johns C. et al. Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020; 30: 4918-4929
  CrossrefPubMedGoogle Scholar
• 37 Johns CS, Rajaram S, Capener DA. et al. Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging. Eur Radiol 2018; 28: 1438-1448
  CrossrefPubMedGoogle Scholar
• 38 Boerrigter BG, Bogaard HJ, Trip P. et al. Ventilatory and Cardiocirculatory Exercise Profiles in COPD: The Role of Pulmonary Hypertension. Chest 2012; 142: 1166-1174
  CrossrefPubMedGoogle Scholar
• 39 Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med 2010; 104: 121-126
  CrossrefPubMedGoogle Scholar
• 40 Kovacs G, Avian A, Bachmaier G. et al. Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic Approach. Chest 2022; 162: 202-212
  CrossrefPubMedGoogle Scholar
• 41 Waxman A, Restrepo-Jaramillo R, Thenappan T. et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021; 384: 325-334
  CrossrefPubMedGoogle Scholar
• 42 Kovacs G, Avian A, Pienn M. et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med 2014; 190: 252-257
  CrossrefPubMedGoogle Scholar
• 43 Ulrich S, Nussbaumer-Ochsner Y, Vasic I. et al. Cerebral oxygenation in patients with OSA: effects of hypoxia at altitude and impact of acetazolamide. Chest 2014; 146: 299-308
  CrossrefPubMedGoogle Scholar
• 44 Schiess R, Senn O, Fischler M. et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010; 138: 1086-1092
  CrossrefPubMedGoogle Scholar
• 45 Blanco I, Santos S, Gea J. et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42: 982-992
  CrossrefPubMedGoogle Scholar
• 46 Raghu G, Behr J, Brown KK. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-649
  CrossrefPubMedGoogle Scholar
• 47 Ghofrani HA, Wiedemann R, Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900
  CrossrefPubMedGoogle Scholar
• 48 Stolz D, Rasch H, Linka A. et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628
  CrossrefPubMedGoogle Scholar
• 49 Olschewski H, Ghofrani HA, Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600-607
  CrossrefPubMedGoogle Scholar
• 50 Lederer DJ, Bartels MN, Schluger NW. et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9: 268-275
  CrossrefPubMedGoogle Scholar
• 51 Goudie AR, Lipworth BJ, Hopkinson PJ. et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014; 2: 293-300
  CrossrefPubMedGoogle Scholar
• 52 Vitulo P, Stanziola A, Confalonieri M. et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart Lung Transplant 2017; 36: 166-174
  CrossrefPubMedGoogle Scholar
• 53 Valerio G, Bracciale P, Grazia DʼAgostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009; 3: 15-21
  CrossrefPubMedGoogle Scholar
• 54 King TEJ, Brown KK, Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99
  CrossrefPubMedGoogle Scholar
• 55 King TEJ, Behr J, Brown KK. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81
  CrossrefPubMedGoogle Scholar
• 56 Idiopathic Pulmonary Fibrosis Clinical Research Network. Zisman DA, Schwarz M, Anstrom KJ. et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628
  CrossrefPubMedGoogle Scholar
• 57 Kolb M, Raghu G, Wells AU. et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 2018; 379: 1722-1731
  CrossrefPubMedGoogle Scholar
• 58 Han MK, Bach DS, Hagan PG. et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013; 143: 1699-1708
  CrossrefPubMedGoogle Scholar
• 59 Corte TJ, Keir GJ, Dimopoulos K. et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014; 190: 208-217
  CrossrefPubMedGoogle Scholar
• 60 Raghu G, Nathan SD, Behr J. et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015; 46: 1370-1377
  CrossrefPubMedGoogle Scholar
• 61 Nathan SD, Behr J, Collard HR. et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019; 7: 780-790
  CrossrefPubMedGoogle Scholar
• 62 Behr J, Nathan SD, Wuyts WA. et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 85-95
  CrossrefPubMedGoogle Scholar
• 63 Nathan SD, Tapson VF, Elwing J. et al. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. Am J Respir Crit Care Med 2022; 205: 198-207
  CrossrefPubMedGoogle Scholar
• 64 Gall H, Felix JF, Schneck FK. et al. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant 2017; 36: 957-967
  CrossrefPubMedGoogle Scholar
• 65 Hoeper MM, Behr J, Held M. et al. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One 2015; 10: e0141911
  CrossrefPubMedGoogle Scholar
• 66 Waxman A, Restrepo-Jaramillo R, Thenappan T. et al. Long-term inhaled treprostinil for PH-ILD: INCREASE open-label extension study. Eur Respir J 2023; 61: 2202414
  CrossrefPubMedGoogle Scholar
• 67 Rosenkranz S, Delcroix M, Giannakoulas G. et al. The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2023; 44: 792-793
  CrossrefPubMedGoogle Scholar